MedTrace Logo

Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer

NCT03225989 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2024-11-19

Study results available
· View outcomes & findings →

Summary

This Phase I/II trial evaluates LOAd703 in patients with cancer (pancreatic, biliary, colorectal or ovarian) together with their standard of care chemotherapy or using gemcitabine immune-conditioning. LOAd703 is administered by intratumoral image-guided injections. Maximum 50 patients can be enrolled.

LOAd703 is an immunostimulatory gene therapy using an selection replication competent adenovirus as a gene vehicle. The virus is derived from serotype 5 adenovirus with the fiber from serotype 35. It expresses the transgenes trimerized membrane-bound isoleucine zipper (TMZ) TMZ-CD40L and 41BBL under control of a cytomegalovirus (CMV) promoter.

Conditions

Interventions

DRUG

LOAd703

Oncolytic adenovirus serotype 5/35 encoding TMZ-CD40L and 4-1BBL

Sponsors & Collaborators

  • Uppsala University

    collaborator OTHER

  • Lokon Pharma AB

    lead INDUSTRY

Principal Investigators

  • Angelica Loskog, PhD · Lokon Pharma AB

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2023-08-22
Completion
2023-08-22
FDA Drug
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03225989 on ClinicalTrials.gov